P atient unmet needs from neurologic disorders are staggering, and the cost to society is enormous. As most OECD countries see a “greying” of their populations, the burdens of many of these later-onset neurologic conditions will skyrocket. All of this creates an imperative to act – and to invest in new therapies. Neuroscience venture funding in the past five years is 40% higher than it was in the prior five years, with most of that increase coming in the last few years.